PMID: 8993486Dec 16, 1996Paper

Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging

Annals of the New York Academy of Sciences
Gary W SmallA D Roses

Abstract

New treatments for Alzheimer's disease (AD) are more likely to slow or halt disease progression rather than to reverse existing neuronal damage. Identifying persons with mild cognitive complaints who are at risk for AD will allow investigators to apply anti-dementia treatments before extensive brain damage develops. The discovery of the apolipoprotein E epsilon 4 allele (APOE epsilon 4) as a major risk factor for AD offers promise of assisting in early detection and prediction of Alzheimer's disease, particularly when genetic assessments are combined with other biomarkers such as neuroimaging. Studies of relatives at risk for familial AD using neuroimaging (positron emission tomography [PET]) and genetic assessments of APOE suggest that at-risk relatives with APOE epsilon 4 have lower parietal metabolism than those without APOE epsilon 4. Additional techniques that might increase sensitivity and specificity include longitudinal assessment of clinical and brain functional change, pharmacological challenges of short-acting anticholinergic agents, and memory activation paradigms during functional scanning. Such strategies should eventually assist in early detection of AD and in vivo therapeutic monitoring of brain function during ...Continue Reading

References

Oct 1, 1977·Journal of Neurology, Neurosurgery, and Psychiatry·W B MatthewsE Pountney
Apr 1, 1976·Journal of Neurology, Neurosurgery, and Psychiatry·H J HannayA L Benton
Oct 1, 1992·Seminars in Nuclear Medicine·J C MazziottaM E Phelps
Jul 1, 1992·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·H W Müller-GärtnerJ J Frost
Feb 11, 1992·Journal of the American Geriatrics Society·B H GuzeM E Phelps
Mar 1, 1991·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·C M ClarkM R Hayden
Nov 10, 1989·JAMA : the Journal of the American Medical Association·D A EvansJ O Taylor
May 1, 1988·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A D SadovnickB L Beattie
Feb 1, 1986·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·P HerscovitchM E Raichle
Jul 1, 1986·Neurology·R DuaraS I Rapoport
Jun 1, 1987·Journal of Neurology, Neurosurgery, and Psychiatry·R J PolinskyR T Brown
Mar 22, 1995·JAMA : the Journal of the American Medical Association·G W SmallL Chang
May 1, 1994·Nature Genetics·K OkuizumiS Naruse
Mar 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·W J StrittmatterA D Roses
May 1, 1993·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·N P AzariB Horwitz

❮ Previous
Next ❯

Citations

Jul 3, 2004·European Journal of Nuclear Medicine and Molecular Imaging·Bich-Ngoc-Thanh TangThierry Vander Borght
Nov 6, 2002·Journal of the Neurological Sciences·Andreas K Demetriades
Feb 19, 2002·Neurochemistry International·Gary E Gibson, Hui Zhang
Oct 1, 2003·Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T·Barbara E. SwartzMark M. Mandelkern
Nov 30, 2002·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·George PerryMark A Smith
Sep 12, 2006·Journal of the International Neuropsychological Society : JINS·Elizabeth W TwamleyMark W Bondi
Jun 12, 2013·Nature Reviews. Neurology·Jessica B LangbaumEric M Reiman
Jun 13, 2000·Alzheimer Disease and Associated Disorders·V Jelic, A Nordberg
Dec 20, 2007·Alzheimer Disease and Associated Disorders·Qingli Shi, Gary E Gibson
Apr 2, 2005·Psychiatry·Murray A Raskind
Apr 14, 2012·Journal of Aging Research·Ana I DuarteCatarina R Oliveira
Nov 12, 2014·Annual Review of Pathology·Harry V Vinters
Jul 2, 2016·Expert Review of Neurotherapeutics·Susana CardosoPaula I Moreira
Aug 2, 2006·Journal of Geriatric Psychiatry and Neurology·Trey SunderlandRobert M Cohen
Apr 28, 2006·Current Opinion in Psychiatry·Gauri Nayak Savla, Barton W Palmer
Jan 27, 1999·Annals of Medicine·H S Soininen, P Scheltens
Jun 6, 2007·Journal of Neuropathology and Experimental Neurology·Paula I MoreiraGeorge Perry
Jul 10, 2001·Aging : Clinical and Experimental Research·L S Honig, R Mayeux
Jan 26, 2011·Ageing Research Reviews·Sónia C CorreiaMark A Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.